New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone … – PR Newswire (press release)
|
New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone …
PR Newswire (press release) Regen BioPharma, Inc. (OTC: RGBP) reported today the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate, the Company's proprietary aplastic anemia cell therapy drug candidate. The experiment is … Regen BioPharma, Inc. Reports Successful Dosing of HemaXellerate in FDA … |
